home / stock / trypf / trypf articles
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangeme...
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exoph...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Colum...